Skip to content

Magenta nabs NIH grant to fund HIV cure research

September 2, 2020

Magenta Therapeutics (MGTA -3.1%) is a co-recipient of a five-year $14.6M NIH grant aimed at exploring the use of gene therapies and cell-based therapies to cure HIV.

The company, along with researchers from six academic/clinical institutions, will investigate novel hematopoietic stem and progenitor cell (HSPC) engineering and transplantation approaches aimed at achieving complete remission of HIV-1 infection.

Magenta will use its conditioning technology to optimize cell dose in animal models and determine whether targeted conditioning and gene-modified HSPC transplant enables disease control.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: